AllSci News
Lilly’s triple agonist retatrutide drives up to 28.7% weight loss and pain relief in Phase 3 TRIUMPH-4
Eli Lilly and Company’s investigational triple hormone receptor agonist retatrutide delivered substantial weight loss and meaningful relief from osteoarthritis pain in the…
Roche trumpets 30% cut to recurrence risk in ER+ breast cancer for SERD giredestrant
Roche announced that its experimental oral selective estrogen receptor degrader (SERD), giredestrant, significantly reduced the risk of invasive disease recurrence or death…
J&J’s Tecvayli combo delivers “remarkable” Phase 3 results in 2nd-line r/r MM
Johnson & Johnson (J&J)’s investigational combination of Tecvayli (teclistamab-cqyv) plus Darzalex Faspro (daratumumab + hyaluronidase) has shown remarkable efficacy in the Phase…
Hemab’s sutacimig set to be first prophylaxis for Glanzmann thrombasthenia
Denmark-based Hemab Therapeutics announced that its Phase 2 study for sutacimig in Glanzmann thrombasthenia (GT) delivered strong, “clinically meaningful” reductions in treated…
Pfizer boasts strong data for Hympavzi in inhibitor-positive hemophilia
Pfizer reported new Phase 3 data showing that Hympavzi (marstacimab) reduced treated annualized bleeding rate (ABR) by 93% compared with on-demand bypassing…
Praxis halts relutrigine trial early after efficacy signal in SCN2A/SCN8A epileptic encephalopathies
Praxis Precision Medicines said positive efficacy data have prompted the independent data monitoring committee to recommend an early stop to the registrational…
Capricor goes from HOPE-3 to promise after deramiocel’s Phase 3 success in Duchenne muscular dystrophy
Capricor Therapeutics trumpeted success in the pivotal Phase 3 HOPE-3 clinical trial for deramiocel as a treatment for boys and young men…
BMS’s CD19 CAR-T Breyanzi breaks ground with indication nod for MZL
Bristol Myers Squibb announced US FDA indication approval for Breyanzi (lisocabtagene maraleucel; liso-cel) as a treatment for adult patients with relapsed or…
BMS to continue Phase III ADEPT-2 for Cobenfy in Alzheimer’s-related psychosis after site irregularities
Bristol Myers Squibb will enrol additional patients into its Phase III ADEPT-2 trial of Cobenfy/KarXT (xanomeline/trospium) for psychosis associated with Alzheimer’s disease…
HopeMed takes fast-track status for first-in-class endometriosis antibody HMI-115
Shanghai, China-based biotech Hope Medicine Inc. (HopeMed) announced that the US FDA has granted Fast Track Designation (FTD) for HMI-115, the company’s…
Imvax achieves survival boost in glioblastoma with IGV-001
Imvax, a biotech based in Philadelphia, announced top-line results from a randomized, multicenter Phase 2b trial for IGV-001 in patients with newly…
Janux posts Phase 1 data for PSMA-directed TCE in mCRPC
San Diego-based biotech Janux Therapeutics released updated interim data from its Phase 1 clinical trial of JANX007, a first-in-class, PSMA-targeted T-cell engager…
Generate:Biomedicines advances AI-engineered asthma antibody into global Phase 3 trials with twice-yearly dosing
Generate:Biomedicines announced plans to launch two global Phase 3 clinical trials, SOLAIRIA-1 and SOLAIRIA-2, to evaluate GB-0895, a long-acting anti-TSLP monoclonal antibody…
IDEAYA’s first-in-class B7H3/PTK7 ADC to enter the clinic following FDA IND
US biotech IDEAYA Biosciences has secured US FDA clearance for an Investigational New Drug (IND) application for IDE034, a potential global first-in-class…
Innovent secures China approval for first domestic IL-23p19 antibody picankibart
China’s National Medical Products Administration (NMPA) issued a first market approval to Innovent Biologics’ Pecondle (picankibart), the country’s first domestically developed IL-23p19…
The AllSci Brief
Systematic R&D and deal news. Daily.